Skip to main content Accessibility help
×
Home

Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012

  • B. GU (a1) (a2), M. ZHOU (a1) (a2), X. KE (a1) (a2), S. PAN (a1) (a2), Y. CAO (a1) (a2), Y. HUANG (a1) (a2), L. ZHUANG (a3), G. LIU (a1) (a2) and M. TONG (a1) (a2)...

Summary

We conducted a systematic review to compare resistance to third-generation cephalosporins (TGCs) in Shigella strains between Europe-America and Asia-Africa from 1998 to 2012 based on a literature search of computerized databases. In Asia-Africa, the prevalence of resistance of total and different subtypes to ceftriaxone, cefotaxime and ceftazidime increased markedly, with a total prevalence of resistance up to 14·2% [95% confidence interval (CI) 3·9–29·4], 22·6% (95% CI 4·8–48·6) and 6·2% (95% CI 3·8–9·1) during 2010–2012, respectively. By contrast, resistance rates to these TGCs in Europe-America remained relatively low – less than 1·0% during the 15 years. A noticeable finding was that certain countries both in Europe-America and Asia-Africa, had a rapid rising trend in the prevalence of resistance of S. sonnei, which even outnumbered S. flexneri in some periods. Moreover, comparison between countries showed that currently the most serious problem concerning resistance to these TGCs appeared in Vietnam, especially for ceftriaxone, China, especially for cefotaxime and Iran, especially for ceftazidime. These data suggest that monitoring of the drug resistance of Shigella strains should be strengthened and that rational use of antibiotics is required.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012
      Available formats
      ×

Copyright

Corresponding author

* Author for correspondence: Dr S. Pan, Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. (Email: sypan@njmu.edu.cn)

Footnotes

Hide All

These authors contributed equally to this work.

Footnotes

References

Hide All
1. Niyogi, SK, Mitra, U, Dutta, P. Changing patterns of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India. Japanese Journal of Infectious Disease 2001; 54: 121122.
2. Vinh, H, et al. A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation. BMC Infectious Disease 2009; 9: 204.
3. Jamsheer, AE, et al. Trend of antibiotic resistance in 1316 Shigella strains isolated in Bahrain. Saudi Medical Journal 2003; 24: 424426.
4. Chompook, P, et al. Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study. Bulletin of the World Health Organization 2005; 83: 739746.
5. Yang, HCG, et al. Surveillance of antimicrobial susceptibility patterns among Shigella species isolated in China during the 7-year period of 2005–2011. Annals of Laboratory Medicine 2013; 33: 111115.
6. Kosek, M, Bern, C, Guerrant, RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bulletin of the World Health Organization 2003; 81: 197204.
7. Bryce, J, et al. WHO estimates of the causes of death in children. Lancet 2005; 365: 11471152.
8. Kotloff, KL, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bulletin of the World Health Organization 1999; 77: 651666.
9. WHO. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type. Geneva: World Health Organization.
10. Sur, D, et al. Shigellosis: challenges and management issues. Indian Journal of Medical Research 2004; 120: 454462.
11. Bhattacharya, SK, Sur, D. An evaluation of current shigellosis treatment. Expert Opinion in Pharmacotherapy 2003; 4: 13151320.
12. Watanabe, T. Infective heredity of multiple drug resistance in bacteria. Bacteriological Reviews 1963; 27: 87115.
13. Sack, RB, et al. Antimicrobial resistance in organisms causing diarrheal disease. Clinical Infectious Disease 1997; 24 (Suppl. 1): S102S105.
14. Bhattacharya, K, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatrica 1997; 86: 319320.
15. Green, S TG, Tilloston, G. Use of Ciprofloxacinrofloxacin in developing countries. Pediatric Infectious Disease Journal 1997; 16: 150159.
16. Gu, B, et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. International Journal of Antimicrobial Agents 2012; 40: 917.
17. Gu, B, et al. Prevalence and trends monitoring of aminoglycoside resistance in Shigella worldwide, 1999–2010. Journal of Biomedical Research 2013; 27: 103115.
18. Fortineau, N, et al. SHV-type extended spectrum-lactamase in a Shigella flexneri clinical isolate. Journal of Antimicrobial Chemotherapy 2001; 47: 685688.
19. Rahman, M, et al. Extended-spectrum beta-lactamase-mediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh. Journal of Antimicrobial Chemotherapy 2004; 54: 846847.
20. Goel, N, et al. Emergence of ceftriaxone resistant Shigella . Indian Journal of Pediatrics 2013; 80: 7071.
21. Vinh, H, et al. Rapid emergence of third-generation cephalosporin resistant Shigella spp. in Southern Vietnam. Journal of Medical Microbiology 2009; 58: 281283.
22. Taneja, N, et al. Cephalosporin-resistant Shigella flexneri over 9 years (2001–09) in India. Journal of Antimicrobial Chemotherapy 2012; 67: 13471353.
23. Freeman, MF TJ. Transformations related to the angular and square root. Annals of the Institute of Statistical Mathematics 1950; 21: 607611.
24. Tiruneh, M. Serodiversity and antimicrobial resistance pattern of Shigella isolates at Gondar University teaching hospital, Northwest Ethiopia. Japanese Journal of Infectious Disease 2009; 62: 9397.
25. Opintan, J, Newman, MJ. Distribution of serogroups and serotypes of multiple drug resistant Shigella isolates. Ghana Medical Journal 2007; 41: 829.
26. Djie-Maletz, A RK, et al. High rate of resistance to locally used antibiotics among enteric bacteria from children in Northern Ghana. Journal of Antimicrobial Chemotherapy 2008; 61: 13151318.
27. Bonkoungou, IJ, et al. Bacterial and viral etiology of childhood diarrhea in Ouagadougou, Burkina Faso. BMC Pediatrics 2013; 13: 36.
28. Varsano, I, et al. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. Journal of Pediatrics 1991;118:627632
29. Seidlein, LV KD, Ali, M. A multicentre study of shigella diarrhea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Medicine 2006; 3: e353.
30. Srinivasa, H, Baijayanti, M, Raksha, Y. Magnitude of drug resistant Shigellosis: a report from Bangalore. Indian Journal of Medical Microbiology 2009; 27: 358360.
31. Bradford, PA. Extended-spectrumb-lactamases in the 21st century: characterisation, epidemiology and detection of this important resistant threat. Clinical Microbiology Reviews 2001; 14: 933951.
32. Lee, W, et al. CTX-M-55-type extended-spectrum beta-lactamase-producing Shigella sonnei isolated from a Korean patient who had travelled to China. Annals of Laboratory Medicine 2013; 33: 141144.
33. Marchou, B. Traveler's diarrheoa: epidemiology, clinical practice guideline for the prevention and treatment. Presse Medicale 2013; 42: 7681.
34. Jeon, YL, et al. Quinolone-resistant Shigella flexneri isolated in a patient who travelled to India. Annals of Laboratory Medicine 2012; 32:366369.
35. Takeshita, N. Travellers and multi-drug resistance bacteria. Nihon Rinsho 2012; 70: 324328.
36. Mache, AMY, Cowly, S. Shigella serogroups identified from adult diarrhoea out-patients in Addis Ababa, Ethiopia: antibiotic resistance and plasmid profile analysis. East African Medical Journal 1997; 74: 179182.
37. Zhang, CL, et al. Drug resistance and molecular epidemiology of Shigella isolated from children with diarrhea. Zhonghua Er Ke Za Zhi 2012; 50: 777781.
38. Mariani-Kurkdjian, P, Doit, C, Bingen, E. Extended-spectrum beta-lactamase producing-enterobacteria. Arch Pediatrics 2012; 19 (Suppl. 3): S9396.
39. Partridge, SR, et al. Gene cassettes and cassette arrays in mobile resistance integrons. FEMS Microbiology Reviews 2009; 33: 757784.
40. Perez-Moreno, MO, et al. Beta-Lammases, transferable quinolone resistance determinants, and class 1 integron-mediated antimicrobial resistance in human clinical Salmonella enteric isolates of non-Typhimurium serotypes. International Journal of Medical Microbiology 2013; 303: 2531.
41. Ke, X, et al. Epidemiology and molecular mechanism of integron-mediated antibiotic resistance in Shigella . Archives of Microbiology 2011; 193: 767774.
42. Sack, DA HA, Huq, A, Etheridge, M. Is protection against shigellosis induced by natural infection with Pleonasms shigellosis? Lancet 1994; 343: 14131415.
43. Genobile, D, et al. An outbreak of shigellosis in a child care center. Communicable Disease Intelligence Quarterly Report 2004; 28: 225229.
44. Lewis, HC, et al. Outbreaks of Shigella sonnei infections in Denmark and Australia linked to consumption of imported raw baby corn. Epidemiology and Infection 2009; 137: 326334.
45. Cohen, D, et al. Reduction of transmission of shigellosis by control of houseflies (Musca domestica). Lancet 1991; 337: 993997.
46. Holt, KE, et al. Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe. Nature Genetics 2012; 44: 10561059.
47. Yang, H, et al. Serotype distribution and characteristics of antimicrobial resistance in Shigella isolated from Henan province, China, 2001–2008. Epidemiology and Infection 2013; 141: 19461952.
48. Kaminski, RW, Oaks, EV. Inactivated and subunit vaccines to prevent shigellosis. Expert Review of Vaccines 2009; 8: 16931704.
49. Martinez-Becerra, FJ, et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infection and Immunity 2012; 80: 12221231.
50. Steele, D, et al. Vaccines for enteric diseases: a meeting summary. Expert Review of Vaccines 2012; 11: 407409.
51. Levine, MM, et al. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiology 2007; 5: 540553.
52. Osorio, M, Bray, MD, Walker, RI. Vaccine potential for inactivated shigellae . Vaccine 2007; 25: 15811592.
53. Nga do, TT, et al. Antibiotic sales in rural and urban pharmacies in northern Vietnam: an observational study. BMC Pharmacology and Toxicology 2014; 15: 6.
54. Wirtz, VJ, et al. Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries. Tropical Medicine and International Health 2013; 18: 665673.
55. Du, HC, John, DN, Walker, R. An investigation of prescription and over-the-counter supply of opthalmic chloramphenicol in Wales in the 5 years following reclassification. International Journal of Pharmacy Practice 2014; 22: 2027.

Keywords

Type Description Title
WORD
Supplementary materials

Gu Supplementary Material
Supplementary Material

 Word (200 KB)
200 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed